SELECTA BIOSCIENCES INC (SELB) Fundamental Analysis & Valuation

NASDAQ:SELB • US8162121045

0.8812 USD
-0.08 (-8%)
At close: Nov 13, 2023
0.9 USD
+0.02 (+2.13%)
After Hours: 11/13/2023, 8:15:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SELB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

SELB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. SELB may be in some trouble as it scores bad on both profitability and health. SELB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. SELB Profitability Analysis

1.1 Basic Checks

  • SELB had negative earnings in the past year.
  • SELB had a negative operating cash flow in the past year.
SELB Yearly Net Income VS EBIT VS OCF VS FCFSELB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M -60M

1.2 Ratios

  • SELB has a Return On Assets of -25.12%. This is in the better half of the industry: SELB outperforms 77.33% of its industry peers.
  • SELB's Return On Equity of -53.55% is fine compared to the rest of the industry. SELB outperforms 63.67% of its industry peers.
Industry RankSector Rank
ROA -25.12%
ROE -53.55%
ROIC N/A
ROA(3y)-12.13%
ROA(5y)-47.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SELB Yearly ROA, ROE, ROICSELB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SELB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SELB Yearly Profit, Operating, Gross MarginsSELB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SELB Health Analysis

2.1 Basic Checks

  • SELB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SELB has more shares outstanding
  • Compared to 1 year ago, SELB has an improved debt to assets ratio.
SELB Yearly Shares OutstandingSELB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
SELB Yearly Total Debt VS Total AssetsSELB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

  • SELB has an Altman-Z score of -3.16. This is a bad value and indicates that SELB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.16, SELB is in line with its industry, outperforming 44.33% of the companies in the same industry.
  • A Debt/Equity ratio of 0.21 indicates that SELB is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.21, SELB is not doing good in the industry: 69.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC11.18%
SELB Yearly LT Debt VS Equity VS FCFSELB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 4.18 indicates that SELB has no problem at all paying its short term obligations.
  • The Current ratio of SELB (4.18) is comparable to the rest of the industry.
  • A Quick Ratio of 4.18 indicates that SELB has no problem at all paying its short term obligations.
  • The Quick ratio of SELB (4.18) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 4.18
SELB Yearly Current Assets VS Current LiabilitesSELB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. SELB Growth Analysis

3.1 Past

  • SELB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.50%.
  • The Revenue for SELB has decreased by -61.85% in the past year. This is quite bad
  • SELB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 250.30% yearly.
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y250.3%
Sales Q2Q%-86.63%

3.2 Future

  • SELB is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -28.87% yearly.
  • Based on estimates for the next years, SELB will show a very negative growth in Revenue. The Revenue will decrease by -11.85% on average per year.
EPS Next Y-228.11%
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
EPS Next 5Y-28.87%
Revenue Next Year-72.53%
Revenue Next 2Y-37.57%
Revenue Next 3Y-26.62%
Revenue Next 5Y-11.85%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SELB Yearly Revenue VS EstimatesSELB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
SELB Yearly EPS VS EstimatesSELB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. SELB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SELB. In the last year negative earnings were reported.
  • Also next year SELB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SELB Price Earnings VS Forward Price EarningsSELB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SELB Per share dataSELB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • SELB's earnings are expected to decrease with -34.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SELB Dividend Analysis

5.1 Amount

  • SELB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SELB Fundamentals: All Metrics, Ratios and Statistics

SELECTA BIOSCIENCES INC

NASDAQ:SELB (11/13/2023, 8:15:05 PM)

After market: 0.9 +0.02 (+2.13%)

0.8812

-0.08 (-8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)02-29
Inst Owners4.73%
Inst Owner Change0%
Ins Owners2.74%
Ins Owner Change0%
Market Cap135.20M
Revenue(TTM)48.69M
Net Income(TTM)-35.05M
Analysts81.67
Price Target3.57 (305.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.65%
Min EPS beat(2)-57.51%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)-161.99%
Min EPS beat(4)-758.49%
Max EPS beat(4)153.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.2%
Min Revenue beat(2)-53.61%
Max Revenue beat(2)-50.8%
Revenue beat(4)1
Avg Revenue beat(4)-20.74%
Min Revenue beat(4)-53.61%
Max Revenue beat(4)40.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.55%
EPS NY rev (1m)0%
EPS NY rev (3m)15.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)60.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.32
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.12%
ROE -53.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.13%
ROA(5y)-47.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.09%
Cap/Sales 1.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 4.18
Altman-Z -3.16
F-Score2
WACC11.18%
ROIC/WACCN/A
Cap/Depr(3y)97.44%
Cap/Depr(5y)77.79%
Cap/Sales(3y)2.43%
Cap/Sales(5y)21.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y-228.11%
EPS Next 2Y-62.59%
EPS Next 3Y-34.35%
EPS Next 5Y-28.87%
Revenue 1Y (TTM)-61.85%
Revenue growth 3Y155.01%
Revenue growth 5Y250.3%
Sales Q2Q%-86.63%
Revenue Next Year-72.53%
Revenue Next 2Y-37.57%
Revenue Next 3Y-26.62%
Revenue Next 5Y-11.85%
EBIT growth 1Y-276.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.04%
OCF growth 3YN/A
OCF growth 5YN/A

SELECTA BIOSCIENCES INC / SELB FAQ

What is the fundamental rating for SELB stock?

ChartMill assigns a fundamental rating of 2 / 10 to SELB.


What is the valuation status for SELB stock?

ChartMill assigns a valuation rating of 0 / 10 to SELECTA BIOSCIENCES INC (SELB). This can be considered as Overvalued.


What is the profitability of SELB stock?

SELECTA BIOSCIENCES INC (SELB) has a profitability rating of 1 / 10.